Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109249 | 0.94 | CTSB (0.52) | CTSSCTSKCTSBMMP13SYK | |
| SCHEMBL1105581 | 0.91 | HDAC1 (0.46) | CTSSCTSKCTSLCTSBMMP13 | |
| SCHEMBL1105583 | 0.90 | CTSB (0.43) | CTSB | |
| SCHEMBL1105673 | 0.88 | — | — | |
| SCHEMBL4232381 | 0.88 | — | — | |
| SCHEMBL14224541 | 0.87 | HDAC1 (0.46) | CTSSCTSKCTSBMMP13 | |
| SCHEMBL1109331 | 0.87 | HDAC1 (0.46) | CTSSCTSKCTSBMMP13 | |
| SCHEMBL13659637 | 0.86 | CTSB (0.47) | CTSSCTSKCTSBMMP13SYK | |
| SCHEMBL1912192 | 0.85 | TAS1R3 (0.52) | CTSSCTSKCTSLSYK | |
| SCHEMBL13818592 | 0.85 | MEN1 (0.50) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSS 300/4885CTSK 430/4885CTSL 127/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSS 300/4885CTSK 430/4885CTSL 127/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSS 300/4885CTSK 430/4885CTSL 127/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CTSS 300/4885CTSK 430/4885CTSL 127/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | CTSS 300/4885CTSK 430/4885CTSL 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.